PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized controlled, prospective clinical trial. The objective is to
investigate the efficacy and safety of Tislelizumab maintenance therapy in newly diagnosed
diffuse large B-cell lymphoma (DLBCL) patients after autologous hematopoietic stem cell
transplantation (ASCT).